$1,318.00
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Chemotherapy-Induced Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Patient subtypes
7 Symptoms
7 Risk factors
7 Diagnosis
9 TREATMENT
9 Iron supplements
9 Blood transfusion
9 Erythropoietin-stimulating agents (ESAs)
11 EPIDEMIOLOGY
13 MARKETED DRUGS
17 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 Roxadustat for CIA (April 6, 2021)
24 PROBABILITY OF SUCCESS
25 LICENSING AND ASSET ACQUISITION DEALS
25 Chong Kun Dang Signs Nesp Biosimilar Deal In Persian Gulf
26 REVENUE OPPORTUNITY
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
31 Recent events
32 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
17 Figure 1: Overview of pipeline drugs for CIA in the US
17 Figure 2: Pipeline drugs for CIA, by company
17 Figure 3: Pipeline drugs for CIA, by drug type
18 Figure 4: Pipeline drugs for CIA, by classification
24 Figure 5: Probability of success in the marrow or peripheral blood stimulator pipeline
28 Figure 6: Clinical trials in CIA
28 Figure 7: Top 10 drugs for clinical trials in CIA
29 Figure 8: Top 10 companies for clinical trials in CIA
30 Figure 9: CIA trials status
31 Figure 10: CIA trials sponsors, by phase
LIST OF TABLES
11 Table 1: Chemotherapy-treated patients with CIA, by grade, in the US
14 Table 2: Marketed drugs for CIA
19 Table 3: Pipeline drugs for CIA in the US
21 Table 4: Roxadustat for CIA (April 6, 2021)
26 Table 5: Historical global sales, by drug ($m), 2017–21
27 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!